

Press Release:

Global GenomicsSM confirms superiority of tangerineTM gene expression profiling

Global Genomics AB revealed today the exceptional performance of the company's innovative technology for gene expression profiling. In a recent study tangerineTM gene expression profiling demonstrated superior sensitivity in detecting gene expression when compared with a leading microarray platform.

A set of well-characterized genes, that were randomly selected, was divided into three categories, corresponding to high, medium and low expression levels. While tangerine and the microarray platform performed equally well within the high expression category, tangerine profiling correctly identified over 40% more genes within the low expression category. Moreover, a higher sensitivity was also evident in the medium category. Level of expression in the low category ranged between 1 and 10 copies per 100,000 transcripts. Studies were performed on mouse liver tissue and validated by real-time PCR.

Dr. Ulf Boberg, CEO of Global Genomics stated, "This study supports our performance capabilities recently published in the article: "Cracking the entrenched arrays" in the March 8 Bernstein Report by BioCentury and strengthens the basis for the company's proposal to the FDA for promoting state of the art technologies in its draft guidance on pharmacogenomic data submissions. Companies can maximize the value of their drug discovery programs and downstream investments by employing more reliable data from the tangerine platform in target identification and lead validation, and thus, compress the years involved in developing new drug candidates."

About Global Genomics

Global Genomics develops and out-licenses innovative tools in functional genomics that provide unique insight into healthy, diseased or drug-treated cells. The company's expertise in advanced molecular biology techniques and computational analysis has resulted in the recent launch of tangerineTM gene expression profiling, a proprietary solution that reveals a whole genome expression profile in a single experiment.

High coverage and sensitivity ensure complete profiles of expressed genes, giving researchers the ability to study gene regulation in any disease or eukaryotic model, since there is no prerequisite for sequence data. The tangerine technology is made up of three proprietary modules: tangerine fragment display, tangerine expression profile and tangerine gene assignment, which are based on PCR, capillary electrophoresis and algorithms that generate gene expression profiles.

Incorporating such comprehensive gene expression profiling at key stages in drug discovery significantly improves selection of targets and lead compounds, leading to well-validated drug candidates and expediting development of a strong pharmaceuticals portfolio.

To meet company representatives and learn more about tangerine profiling, stop by the Global Genomics Booth #6358 at BIO 2004 in San Francisco between June 7 and 9th.

For further information, visit www.globalgenomics.com or contact:

Ulf Boberg, Chief Executive Officer
Email: uboberg@globalgenomics.com
Tel: +46 8 508 84711
Mobile: +46 73 312 4490

Martin Vidaeus, Director of Business Development
Email: mvidaeus@globalgenomics.com
Tel: +46 8 508 84729
Mobile: +46 70 232 2929

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Although based on the company's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from those expressed herein. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

The Global Genomics (SM) logo and tangerine (TM) are service and trademarks, respectively, of Global Genomics AB.